1255667-06-1

Basic information

• Product Name: 1-Tert-butyl 3-Methyl 5,5-difluoropiperidine-1,3-dicarboxylate
• Synonyms: 1-Tert-butyl 3-Methyl 5,5-difluoropiperidine-1,3-dicarboxylate;1-tert-Butyl 3-methyl 5,5-difluoropiperidine-1,3-dicarboxylate, 1-(tert-Butoxycarbonyl)-3,3-difluoro-5-(methoxycarbonyl)piperidine;Methyl 5,5-difluoropiperidine-3-carboxylate, N-BOC protected;Methyl 1-Boc-5,5-difluoro-3-piperidinecarboxylate;N-t-BOC-3-Methyl-5,5-difluoropiperidine-3-carboxylate;1-O-tert-butyl 3-O-methyl 5,5-difluoropiperidine-1,3-dicarboxylate
• CAS NO: 1255667-06-1
• Molecular Formula: C12H19F2NO4
• Molecular Weight: 279.2803664
• Mol File: 1255667-06-1.mol

Chemical Properties

• Boiling Point: 311.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -6.54±0.60(Predicted)
• CAS DataBase Reference: 1-Tert-butyl 3-Methyl 5,5-difluoropiperidine-1,3-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Tert-butyl 3-Methyl 5,5-difluoropiperidine-1,3-dicarboxylate(1255667-06-1)
• EPA Substance Registry System: 1-Tert-butyl 3-Methyl 5,5-difluoropiperidine-1,3-dicarboxylate(1255667-06-1)

Safety Data

• Hazardous Substances Data: 1255667-06-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-Tert-butyl 3-Methyl 5,5-difluoropiperidine-1,3-dicarboxylate is used as a building block for the synthesis of various biologically active compounds, contributing to the development of new drugs due to its ability to target specific receptors and biological pathways.
Used in Drug Discovery and Development:
1-Tert-butyl 3-Methyl 5,5-difluoropiperidine-1,3-dicarboxylate is employed as a valuable tool in drug discovery and development processes, owing to its unique molecular structure and properties that facilitate the creation of novel therapeutic agents.
Used as a Reference Standard in Analytical Chemistry:
1-Tert-butyl 3-Methyl 5,5-difluoropiperidine-1,3-dicarboxylate is used as a reference standard for the determination of piperidine derivatives in various samples, ensuring the accuracy and reliability of analytical results in the field of chemistry.

Upstream product

• 1095010-47-1 1-(1,1-dimethylethyl) 3-methyl 5-hydroxy-1,3-piperidinedicarboxylate 
• 1303974-96-0 1-(tert-butyl) 3-methyl 5-oxopiperidine-1,3-dicarboxylate 
• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 
• 27828-71-3 5-hydroxynicotinic acid 
• 1095010-44-8 methyl 5-hydroxypiperidine-3-carboxylate 
• 1095010-48-2 1-(tert-butoxycarbonyl)-5-hydroxypiperidine-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1956365-99-3 C₁₅H₁₇NO₅ 
• 1095010-45-9 O₁-benzyl O₃-methyl 5-hydroxypiperidine-1,3-dicarboxylate 

Downstream Products

• 1262412-64-5 tert-butyl 3,3-difluoro-5-(hydroxymethyl)piperidine-1-carboxylate 
• 1255666-86-4 1-(tert-butoxycarbonyl)-5,5-difluoropiperidine-3-carboxylic acid 

Relevant articles and documents

QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.

DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF

The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but no

INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME

Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor ("MRTF/SRF"), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.

NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R1 represents optionally substituted C1-4 alkyl, n shows integer of 1 to 4, R2 represents optionally substituted C1-4 alkyl or hydrogen atom, R3 represents optionally substituted C1-4 alkyl, R4a, R4b, R4c, and R4d, similarly or differently, represent optionally substituted C6-14 aryl, optionally substituted C1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

SUBSTITUTED [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS

The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, and Ar are as defined herein, are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders using such compounds.

SERINE/THREONINE KINASE INHIBITORS

Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, and Ar are as defined herein, are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.